Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (10): 939-944.DOI: 10.3969/j.issn.1673-8640.2024.10.003
Previous Articles Next Articles
ZHU Longyin, PAN Qianguang, YANG Sha, ZENG Yuqin, FU Chunxiao, PU Youmin, FANG Jia, YAN Chunyan, ZHAO Hongwen()
Received:
2023-07-04
Revised:
2024-07-25
Online:
2024-10-30
Published:
2024-11-08
CLC Number:
ZHU Longyin, PAN Qianguang, YANG Sha, ZENG Yuqin, FU Chunxiao, PU Youmin, FANG Jia, YAN Chunyan, ZHAO Hongwen. Early warning value of whole blood cell derived inflammatory markers for delayed graft function of renal transplantation[J]. Laboratory Medicine, 2024, 39(10): 939-944.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.10.003
组别 | 例数 | 年龄/岁 | 性别 | 透析类型 | 热缺血 时间/min | 冷缺血 时间/h | ||||
---|---|---|---|---|---|---|---|---|---|---|
男/例 | 女/例 | 腹膜透析/ 例 | 血液透析/ 例 | 腹膜透析+ 血液透析/ 例 | 未透析/ 例 | |||||
DGF组 | 33 | 36.0(29.0,45.5) | 25 | 8 | 7 | 24 | 2 | 0 | 5(5,5) | 4(4,9) |
IGF组 | 158 | 34.0(27.0,45.0) | 108 | 50 | 24 | 128 | 2 | 4 | 5(2,5) | 4(2,6) |
统计值 | 2 461.000 | 0.708 | 4.123 | 1 611.000 | 1 896.500 | |||||
P值 | 0.613 | 0.400 | 0.183 | <0.001 | 0.013 | |||||
组别 | 手术时间/min | 出院时SCr/ (μmol·L-1) | 慢性基础病 | 术前SCr/ (μmol·L-1) | ||||||
糖尿病 | 高血压 | |||||||||
DGF组 | 188.00(135.50,211.50) | 179.00(138.75,219.35) | 1 | 32 | 1 130.90(851.60,1 230.27) | |||||
IGF组 | 166.50(135.00,187.75) | 118.20(92.95,154.68) | 5 | 138 | 982.60(773.20,1 168.36) | |||||
统计值 | 2 097.500 | 1 237.000 | 0.000 | 1.696 | 2 066.500 | |||||
P值 | 0.078 | <0.001 | 1.000 | 0.193 | 0.061 | |||||
组别 | WBC计数/ (×109·L-1) | Hb/ (g·L-1) | PLT计数/ (×109·L-1) | NEUT#/ (×109·L-1) | LYMPH#/(×109·L-1) | MO#/ (×109·L-1) | ||||
DGF组 | 7.03(4.79,8.15) | 114.06±23.72 | 209.12±58.38 | 5.19(3.43,6.58) | 1.09±0.39 | 0.43(0.32,0.55) | ||||
IGF组 | 5.80(4.85,7.08) | 115.87±20.25 | 191.32±63.14 | 4.03(3.10,4.95) | 1.35±0.40 | 0.41(0.31,0.51) | ||||
统计值 | 2 002.000 | -0.454 | 1.491 | 1 765.000 | -3.314 | 2 398.500 | ||||
P值 | 0.036 | 0.651 | 0.138 | 0.004 | 0.001 | 0.470 |
组别 | 例数 | 年龄/岁 | 性别 | 透析类型 | 热缺血 时间/min | 冷缺血 时间/h | ||||
---|---|---|---|---|---|---|---|---|---|---|
男/例 | 女/例 | 腹膜透析/ 例 | 血液透析/ 例 | 腹膜透析+ 血液透析/ 例 | 未透析/ 例 | |||||
DGF组 | 33 | 36.0(29.0,45.5) | 25 | 8 | 7 | 24 | 2 | 0 | 5(5,5) | 4(4,9) |
IGF组 | 158 | 34.0(27.0,45.0) | 108 | 50 | 24 | 128 | 2 | 4 | 5(2,5) | 4(2,6) |
统计值 | 2 461.000 | 0.708 | 4.123 | 1 611.000 | 1 896.500 | |||||
P值 | 0.613 | 0.400 | 0.183 | <0.001 | 0.013 | |||||
组别 | 手术时间/min | 出院时SCr/ (μmol·L-1) | 慢性基础病 | 术前SCr/ (μmol·L-1) | ||||||
糖尿病 | 高血压 | |||||||||
DGF组 | 188.00(135.50,211.50) | 179.00(138.75,219.35) | 1 | 32 | 1 130.90(851.60,1 230.27) | |||||
IGF组 | 166.50(135.00,187.75) | 118.20(92.95,154.68) | 5 | 138 | 982.60(773.20,1 168.36) | |||||
统计值 | 2 097.500 | 1 237.000 | 0.000 | 1.696 | 2 066.500 | |||||
P值 | 0.078 | <0.001 | 1.000 | 0.193 | 0.061 | |||||
组别 | WBC计数/ (×109·L-1) | Hb/ (g·L-1) | PLT计数/ (×109·L-1) | NEUT#/ (×109·L-1) | LYMPH#/(×109·L-1) | MO#/ (×109·L-1) | ||||
DGF组 | 7.03(4.79,8.15) | 114.06±23.72 | 209.12±58.38 | 5.19(3.43,6.58) | 1.09±0.39 | 0.43(0.32,0.55) | ||||
IGF组 | 5.80(4.85,7.08) | 115.87±20.25 | 191.32±63.14 | 4.03(3.10,4.95) | 1.35±0.40 | 0.41(0.31,0.51) | ||||
统计值 | 2 002.000 | -0.454 | 1.491 | 1 765.000 | -3.314 | 2 398.500 | ||||
P值 | 0.036 | 0.651 | 0.138 | 0.004 | 0.001 | 0.470 |
组别 | 例数 | NLR | PLR | MLR | SII | SIRI |
---|---|---|---|---|---|---|
DGF组 | 33 | 4.28 (3.19,6.61) | 179.59 (149.67,273.49) | 0.39 (0.29,0.63) | 859.02 (645.17,1 314.62) | 2.30 (1.04,3.03) |
IGF组 | 158 | 3.03 (2.27,4.05) | 145.31 (103.74,186.79) | 0.31 (0.24,0.39) | 562.07 (369.22,849.42) | 1.21 (0.77,1.89) |
U值 | 1 375.500 | 1 582.500 | 1 696.000 | 1 335.000 | 1 582.500 | |
P值 | <0.001 | <0.001 | 0.002 | <0.001 | <0.001 |
组别 | 例数 | NLR | PLR | MLR | SII | SIRI |
---|---|---|---|---|---|---|
DGF组 | 33 | 4.28 (3.19,6.61) | 179.59 (149.67,273.49) | 0.39 (0.29,0.63) | 859.02 (645.17,1 314.62) | 2.30 (1.04,3.03) |
IGF组 | 158 | 3.03 (2.27,4.05) | 145.31 (103.74,186.79) | 0.31 (0.24,0.39) | 562.07 (369.22,849.42) | 1.21 (0.77,1.89) |
U值 | 1 375.500 | 1 582.500 | 1 696.000 | 1 335.000 | 1 582.500 | |
P值 | <0.001 | <0.001 | 0.002 | <0.001 | <0.001 |
指标 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
NLR | 0.736(0.667~0.797) | 3.54 | 69.70 | 66.46 | 0.362 |
PLR | 0.696(0.626~0.761) | 150.50 | 75.76 | 54.43 | 0.302 |
MLR | 0.672(0.601~0.738) | 0.38 | 57.58 | 72.78 | 0.304 |
SII | 0.744(0.676~0.804) | 567.69 | 87.88 | 51.90 | 0.398 |
SIRI | 0.696(0.626~0.761) | 2.29 | 51.52 | 87.34 | 0.389 |
联合检测 | 0.801(0.738~0.856) | 0.17 | 72.73 | 75.95 | 0.487 |
指标 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
NLR | 0.736(0.667~0.797) | 3.54 | 69.70 | 66.46 | 0.362 |
PLR | 0.696(0.626~0.761) | 150.50 | 75.76 | 54.43 | 0.302 |
MLR | 0.672(0.601~0.738) | 0.38 | 57.58 | 72.78 | 0.304 |
SII | 0.744(0.676~0.804) | 567.69 | 87.88 | 51.90 | 0.398 |
SIRI | 0.696(0.626~0.761) | 2.29 | 51.52 | 87.34 | 0.389 |
联合检测 | 0.801(0.738~0.856) | 0.17 | 72.73 | 75.95 | 0.487 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
OR值(95%CI) | P值 | OR值(95%CI) | P值 | ||
年龄 | 1.004(0.970~1.040) | 0.806 | |||
BMI | 1.039(0.929~1.163) | 0.502 | |||
冷缺血时间 | 1.159(1.053~1.277) | 0.003 | 1.110(0.989~1.246) | 0.077 | |
热缺血时间 | 1.856(1.278~2.694) | 0.001 | 1.672(1.104~2.533) | 0.015 | |
WBC计数 | 1.335(1.103~1.616) | 0.003 | 0.238(0.007~8.550) | 0.432 | |
LYMPH# | 0.172(0.057~0.517) | 0.002 | 3.544(0.027~470.562) | 0.612 | |
NEUT# | 1.548(1.218~1.968) | <0.001 | 8.233(0.207~327.097) | 0.262 | |
NLR | 1.463(1.197~1.788) | <0.001 | 1.109(0.714~1.723) | 0.645 | |
PLR | 1.010(1.005~1.016) | <0.001 | 1.035(1.008~1.063) | 0.012 | |
MLR | 55.316(6.343~482.385) | <0.001 | 0.000(0.000~27.680) | 0.156 | |
SII | 1.002(1.001~1.003) | <0.001 | 0.994(0.989~1.000) | 0.040 | |
SIRI | 1.801(1.264~2.566) | 0.001 | 6.879(0.766~61.786) | 0.085 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
OR值(95%CI) | P值 | OR值(95%CI) | P值 | ||
年龄 | 1.004(0.970~1.040) | 0.806 | |||
BMI | 1.039(0.929~1.163) | 0.502 | |||
冷缺血时间 | 1.159(1.053~1.277) | 0.003 | 1.110(0.989~1.246) | 0.077 | |
热缺血时间 | 1.856(1.278~2.694) | 0.001 | 1.672(1.104~2.533) | 0.015 | |
WBC计数 | 1.335(1.103~1.616) | 0.003 | 0.238(0.007~8.550) | 0.432 | |
LYMPH# | 0.172(0.057~0.517) | 0.002 | 3.544(0.027~470.562) | 0.612 | |
NEUT# | 1.548(1.218~1.968) | <0.001 | 8.233(0.207~327.097) | 0.262 | |
NLR | 1.463(1.197~1.788) | <0.001 | 1.109(0.714~1.723) | 0.645 | |
PLR | 1.010(1.005~1.016) | <0.001 | 1.035(1.008~1.063) | 0.012 | |
MLR | 55.316(6.343~482.385) | <0.001 | 0.000(0.000~27.680) | 0.156 | |
SII | 1.002(1.001~1.003) | <0.001 | 0.994(0.989~1.000) | 0.040 | |
SIRI | 1.801(1.264~2.566) | 0.001 | 6.879(0.766~61.786) | 0.085 |
[1] |
ZHAO S, LIU Y, ZHOU C, et al. Prediction model of delayed graft function based on clinical characteristics combined with serum IL-2 levels[J]. BMC Nephrol, 2022, 23(1):284.
DOI PMID |
[2] | 中华医学会器官移植学分会. 肾移植术后移植物功能延迟恢复诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(5):521-525. |
[3] | 李峰, 浦金贤, 黄玉华, 等. 肾损伤标志物对肾移植受者发生DGF的早期预测价值[J]. 器官移植, 2022, 13(1):74-79. |
[4] | PONTICELLI C, REGGIANI F, MORONI G. Delayed graft function in kidney transplant:risk factors,consequences and prevention strategies[J]. J Pers Med, 2022, 12(10):1557. |
[5] | BANK J R, VAN DER POL P, VREEKEN D, et al. Kidney injury molecule-1 staining in renal allograft biopsies 10 days after transplantation is inversely correlated with functioning proximal tubular epithelial cells[J]. Nephrol Dial Transplant, 2017, 32(12):2132-2141. |
[6] | 冯梓燕, 梁思宇, 韩伟, 等. 超声造影在移植肾功能延迟恢复中的应用[J]. 暨南大学学报(自然科学与医学版), 2022, 43(4):412-418. |
[7] | ZHOU D, YANG H, ZENG L, et al. Calculated inflammatory markers derived from complete blood count results,along with routine laboratory and clinical data,predict treatment failure of acute peritonitis in chronic peritoneal dialysis patients[J]. Ren Fail, 2023, 45(1):2179856. |
[8] | MANGALESH S, DUDANI S, MALIK A. The systemic immune-inflammation index in predicting sepsis mortality[J]. Postgrad Med, 2023, 135(4):345-351. |
[9] |
BEBERASHVILI I, OMAR M A, NIZRI E, et al. Combined use of CRP with neutrophil-to-lymphocyte ratio in differentiating between infectious and noninfectious inflammation in hemodialysis patients[J]. Sci Rep, 2023, 13(1):5463.
DOI PMID |
[10] | VALGA F, MONZÓN T, HENRIQUEZ F, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as biological markers of interest in kidney disease[J]. Nefrología(Engl Ed), 2019, 39(3):243-249. |
[11] | SATO Y, YANAGITA M. Immune cells and inflammation in AKI to CKD progression[J]. Am J Physiol Renal Physiol, 2018, 315(6):F1501-F1512. |
[12] |
段丽丽, 蒋唱, 周冬梅. PLR在抗核抗体阳性强直性脊柱炎患者中的临床价值[J]. 检验医学, 2023, 38(7):669-674.
DOI |
[13] | 况丽, 杜兰玉, 张洁. 血液透析联合血液灌流对尿毒症患者炎症状态及免疫功能的影响[J]. 临床医学, 2023, 43(4):52-54. |
[14] |
TONYALI S, CEYLAN C, YAHSI S, et al. Does neutrophil to lymphocyte ratio demonstrate deterioration in renal function?[J]. Ren Fail, 2018, 40(1):209-212.
DOI PMID |
[15] | LU X, WANG S, ZHANG G, et al. High neutrophil-to-lymphocyte ratio is a significant predictor of cardiovascular and all-cause mortality in patients undergoing peritoneal dialysis[J]. Kidney Blood Press Res, 2018, 43(2):490-499. |
[16] |
IEK G, AIKGOZ S K, BOZBAY M, et al. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio combination can predict prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Angiology, 2015, 66(5):441-447.
DOI PMID |
[17] | 刘秀琴, 郭俊英, 周旭升. 血常规指标NLR、PLR、LMR联合用于糖尿病肾病诊断及进展评估的临床效果[J]. 糖尿病新世界, 2022, 25(16):50-53. |
[18] | LACQUANITI A, CACCAMO C, SALIS P, et al. Delayed graft function and chronic allograft nephropathy:diagnostic and prognostic role of neutrophil gelatinase-associated lipocalin[J]. Biomarkers, 2016, 21(4):371-378. |
[19] |
BATAILLE A, ABBAS S, SEMOUN O, et al. Plasma neutrophil gelatinase-associated lipocalin in kidney transplantation and early renal function prediction[J]. Transplantation, 2011, 92(9):1024-1030.
DOI PMID |
[20] | ODA T, ISHIMURA T, YOKOYAMA N, et al. Hypoxia-inducible factor-1alpha expression in kidney transplant biopsy specimens after reperfusion is associated with early recovery of graft function after cadaveric kidney transplantation[J]. Transplant Proc, 2017, 49(1):68-72. |
[21] | SARGIN G, SENTURK T, YAVASOGLR I, et al. Relationship between neutrophil-lymphocyte,platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab[J]. Int J Rheum Dis, 2018, 21(12):2122-2127. |
[22] | CHOTAI P N, LOGAN A, SUBRAMANIAN J, et al. Outcomes after deceased donor kidney transplantation using kidney allografts with marginal perfusion parameters[J]. Transplant Proc, 2023, 55(7):1561-1567. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||